Literatur – 8. Bewertung der relevanten verlässlichen Evidenz

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 332: 349–360.

2. Reynolds LA, Tansey EM, eds. Prenatal corticosteroids for reducing morbidity and mortality after preterm birth. London: Wellcome Trust Centre for the History of Medicine, 2005.

3. Dickersin K, Chalmers I. Recognising, investigating and dealing with incomplete and biased reporting of clinical research: from Francis Bacon to the World Health Organisation. James Lind Library 2010 (www.

4. Cowley AJ, Skene A, Stainer K, et al. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. International Journal of Cardiology 1993; 40: 161–166.

5. Moore T. Deadly Medicine. New York: Simon and Schuster, 1995.

6. Stjernswärd J. Decreased survival related to irradiation postoperatively in early operable breast cancer. Lancet 1974; ii: 1285–1286.

7. Stjernswärd J. Meta-analysis as a manifestation of «bondförnuft» («peasant sense»). JLL Bulletin: Commentaries on the history of treatment evaluation 2009 (www.

8. Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold «HRT». PLoS Medicine 2010; 7(9): e1000335.

9. Whittington CJ, Kendall T, Fonagy P, et al. Selective serotonin-reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363: 1341–1345.

10. Spielmans GI, Biehn TL, Sawrey DL. A case study of salami slicing: pooled analysis of duloxetine for depression. Psychotherapy and Psychosomatics 2010; 79: 97–106.

11. Antman EM, Lau J, Kupelnick B, et al. A comparison of results of metaanalysis of randomized control trials and recommendations of clinical experts. JAMA 1992; 268: 240–248.

12. Natanson C, Kern SJ, Lurie P, et al. Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis. JAMA 2008; 299(19): 2304–2312.

13. Chalmers I. TGN1412 and The Lancet’s solicitation of reports of phase 1 trials. Lancet 2006; 368:2206–7.

14. Jack A. Call to release human drug trial data. Financial Times, 8. August 2006.

15. Kenter MJH, Cohen AF. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 2006; 368: 1387–91.

16. McLellan F. 1966 and all that – when is a literature search done? Lancet 2001; 358: 646.

17. Horn J, Limburg M. Calcium antagonists for acute ischemic stroke. Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No.: CD001928.

18. Horn J, de Haan RJ, Vermeulen M, et al. Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke 2001; 32: 2433–2438.

19. O’Collins VE, Macleod MR, Donnan GA, et al. 1,026 experimental treatments in acute stroke. Annals of Neurology 2006; 59: 467–477.

20. CRASH trial collaborators. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury – outcomes at 6 months. Lancet 2005; 365: 1957–1959.